GMMMG Consultations |
|
On this page you will find proposed changes that are currently going through the GMMMG approval process. This will include consultations on proposed RAG status, updated Formulary Chapters, Pathways or other GMMMG Guidance. You will be able to comment on current proposals via the links in the table below. Due to the COVID-19 outbreak all active GMMMG consultations were temporarily suspended in April. The active consultations have now been re-opened; please see below for the new end dates. Every effort has been made to allow sufficient time for appropriate clinical input to these documents, but if you foresee any problems or have any questions please email nuth.enquires.gmmmg@nhs.net |
Title |
Information |
Feedback |
End date |
|
102 |
GMMMG Indigo Transgender Service Shared Care Protocols |
On behalf of the GMMMG Clinical Reference Group, we now seek comments on a series of draft shared care protocols to support the safe transfer of prescribing between Indigo Gender Services and GM primary care prescribers. This consultation contains three SCPs, one for each of; oestrogens, testosterone, and gonadotrophin-releasing hormones (GnRH) analogues, and uses the new GMMMG SCP template. |
5pm Tuesday |
|
101 |
GMMMG Clinical Reference Group- actions proposed at December’s meeting |
On behalf of the GMMMG Clinical Reference Group, we now seek comments on actions proposed at the December meeting. This consultation period is open until 5pm Monday 15th February 2021 |
5pm Monday |
|
100 |
The Greater Manchester-Wide COPD Pathway Development Group is pleased to present an updated version of the GMMMG COPD Management Plan. This revised version is still based on GOLD guidance and has a greater emphasis on low carbon options, as well as further detail for certain topics. Please submit comments by Friday 15th January 2021. The RDTC® is developing a tool which will be made available to CCG Medicines Optimisation teams in the coming weeks to consider the carbon dioxide equivalent values (a standard unit for measuring carbon footprint) alongside the financial impact posed by the different inhaler options. This will enable local teams to identify affordable improvements in their carbon footprint through appropriate inhaler choice based on their current usage and with consideration to the principle of this management plan. |
5pm Friday |
||
99 |
GMMMG Clinical Reference Group- actions proposed at November’s meeting |
On behalf of the GMMMG Clinical Reference Group, we now seek comments [Link removed - consultation closed] on actions [Link removed - consultation closed] proposed at the November meeting. This consultation period is open until 5pm Thursday 31st December 2020. |
Feedback Form |
5pm Thursday |
<< Back